The Danish drugmaker confirmed that it will continue to restrict the lower-dose strengths of Wegovy as it strives to keep up with demand.
Novo Nordisk, which makes blockbuster drug Wegovy, raised its outlook for 2023 Thursday but said it is extending supply restrictions for some doses of the weight-loss drug.
"[T]he supply of the lower dose strengths in the US will remain restricted to safeguard continuity of care," the company said., which makes blockbuster drug Wegovy, raised its outlook for 2023 Thursday but said it is extending supply restrictions for some doses of the weight-loss drug. The Danish pharmaceutical company reported a 30% increase in sales, at constant exchange rates, for the first half of this year to 107.7 million Danish kroner . Net profit increased 43%, coming in at 39.2 million kroner.
The company's diabetes and obesity division performed particularly well, bolstered by interest in its blockbuster injection Wegovy. Feeling out of the loop? We'll catch you up on the Chicago news you need to know. Sign up for the weekly"The [sales] growth is driven by increasing demand for our GLP-1-based diabetes and obesity treatments, and we are serving more patients than ever before," Lars Fruergaard Jørgensen, president and CEO, said in a statement."The performance in the first six months has enabled us to raise the outlook for the full year.
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Wegovy-maker Novo Nordisk raises outlook as sales of its weight-loss drug soarThe Danish company's diabetes and obesity division performed particularly well, bolstered by interest in its blockbuster injection Wegovy.
Read more »
Novo Nordisk weight loss drug Wegovy cuts heart disease risk by 20%, trial showsResults of a late-stage drug trial conducted by Novo Nordisk show that weight loss drug Wegovy can reduce the risk of heart disease in certain patients. Wegovy was approved by the FDA in 2021 for chronic weight management in adults with obesity or overweight and weight-related conditions.
Read more »
Novo Nordisk extends U.S. supply curbs on weight-loss drug WegovyNovo Nordisk will continue to restrict U.S. supplies of starter doses of its hugely popular Wegovy weight-loss drug in the coming quarters, it said on Thursday, as the company struggles to keep up with soaring U.S. demand.
Read more »
Novo weight-loss drug Wegovy shows heart benefit in trialNovo Nordisk announced that a trial has revealed that patients taking the weight-loss drug Wegovy had a 20% lower risk of heart attack, stroke, or death from heart disease compared to those on a placebo. This finding gives hope to Novo Nordisk in expanding the perception of Wegovy beyond being just a lifestyle drug.
Read more »
Novo's Wegovy Shows Heart Benefit Alongside Weight Loss in TrialNovo Nordisk, the maker of Wegovy, announced that a large study has demonstrated the cardiovascular benefits of the highly effective obesity treatment. This finding is significant as it allows the Danish company to expand its market beyond being perceived as a lifestyle drug. The positive results from the trial may also encourage insurers in the U.S. and cost-conscious health authorities in Europe to cover the cost of Wegovy for a wider range of patients.
Read more »
Novo Nordisk to acquire obesity drug maker Inversago Pharma for up to $1 billionInversago's drugs use a different approach than most treatments in the obesity and diabetes space.
Read more »